Intravesical mitomycin C for superficial transitional cell carcinoma

Area of Science:

• Urology
• Oncology
• Chemotherapy

Background:

• Intravesical mitomycin C is a standard treatment post-transurethral resection for superficial bladder tumors.
• It effectively reduces the recurrence rate of transitional cell carcinoma.
• Recent reports highlight potential severe complications associated with its use.

Purpose of the Study:

• To review the mechanism of action and intravesical effects of mitomycin C.
• To outline current indications for intravesical mitomycin C instillation.
• To compare its oncological benefits against other intravesical treatments like bacillus Calmette-Guérin and detail associated complications.

Main Methods:

• Literature review of existing studies and case reports on intravesical mitomycin C.
• Analysis of oncological outcomes and complication profiles.
• Comparative assessment with alternative intravesical therapies.

Main Results:

• Mitomycin C demonstrates efficacy in reducing superficial bladder cancer recurrence post-resection.
• While generally safe, severe adverse events have been documented.
• Comparative data suggests varying efficacy and safety profiles against treatments like bacillus Calmette-Guérin.

Conclusions:

• Intravesical mitomycin C remains a valuable option for superficial bladder cancer management.
• Awareness of potential severe complications is crucial for patient safety.
• Further research may refine its role and comparison with other intravesical agents.